Related Experiment Videos
Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease
1Department of Haematology, Faculty of Medicine, University of Benin, Nigeria.
British Journal of Biomedical Science
|December 1, 1995
Summary
Sickle cell patients show increased platelet factor 3 (PF-3) availability, especially those with thrombocytosis. This enhanced PF-3 release may contribute to vaso-occlusive crises in sickle cell disease.
Area of Science:
- Hematology
- Vascular Biology
- Sickle Cell Disease Pathophysiology
Background:
- Red blood cell membrane alterations in sickle cell disease (SCD) may influence platelet function.
- Platelet Factor 3 (PF-3) availability is crucial for coagulation activation.
Purpose of the Study:
- To investigate the effect of SCD on platelet factor 3 (PF-3) availability.
- To compare PF-3 availability in sickle cell patients (stable and with thrombocytosis) versus healthy controls.
Main Methods:
- Platelet counts and PF-3 availability were measured.
- Study included 30 stable sickle cell patients, 15 sickle cell patients with thrombocytosis, and 60 healthy controls.
Main Results:
- No significant difference in platelet counts between groups.
- Slightly higher PF-3 availability in stable sickle cell patients compared to controls (P < 0.025).
- Significantly greater PF-3 availability in sickle cell patients with thrombocytosis versus controls and stable patients (P < 0.001).
Conclusions:
- Sickle cell patients exhibit readily available PF-3, potentially linked to coagulation activation.
- Enhanced PF-3 availability may play a critical role in the pathogenesis of vaso-occlusive crises in SCD.